1. Oxford BioMedica
Established in 1995 as a spin out from Oxford University,
Oxford BioMedica plc specialises in the development
of novel gene-based therapeutics for the treatment
of cancer, neuro-degenerative disease and other disorders
with major unmet clinical needs. The development pipeline
includes two novel anti-cancer products in clinical
trials and a gene therapy treatment for Parkinson’s
disease, which is in late preclinical studies. This
is underpinned by a broad research pipeline and over
70 patent families, about quarter of which are issued.
Oxford BioMedica’s products use genes as the
mediators of a therapeutic effect and/or immune response.
The Company’s gene therapy products deliver therapeutic
molecules in vivo whilst its gene-based immunotherapy
products deliver genes that recruit the patient’s
immune system to mediate a therapeutic effect. The
genes are delivered by the Company’s highly engineered
viruses or cells.
BioMedica’s lead product TroVax® is an anti-cancer
therapeutic vaccine expected to be useful against a
broad range of tumour types. It is entering Phase II
trials in a number of indications including colorectal
and renal cancer, and is expected to be ready for Phase
III trials at the end of 2003. The Company’s
second cancer product, MetXia®, is completing Phase
I/II studies in breast cancer.
Oxford BioMedica is headquartered in Oxford, UK and
has a wholly-owned subsidiary in San Diego, USA. BioMedica
has corporate collaborations with Wyeth, IDM, Intervet,
Aliga Pharmaceuticals, Amersham and Arius Research.
Oxford BioMedica plc was floated on
the Alternative Investment Market of the London Stock
Exchange in December
1996, and was promoted to the United Kingdom Listing
Authority Official List in April 2001 following a successful £35.5
million fund-raising.
|
